<DOC>
	<DOC>NCT00335374</DOC>
	<brief_summary>This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial</brief_summary>
	<brief_title>An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients who have completed S308.3.003 trial Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (visit M6, week 24) of study S308.3.003</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Parkinson's disease</keyword>
</DOC>